NCT00100048View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

PHASE2CompletedINTERVENTIONAL

Enrollment

206

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

July 31, 2010

Conditions

HIV InfectionsAcquired Immunodeficiency Syndrome

Interventions

DRUG

Comparator: MK0518 monotherapy

MK0518 twice daily for 10 days

DRUG

Comparator: MK0518 combination therapy

MK0518 twice daily for 48 weeks

DRUG

Comparator: efavirenz

efavirenz 600 mg every night at bedtime for 48 weeks

DRUG

Comparator: tenofovir

tenofovir 300 mg daily for 48 weeks

DRUG

Comparator: lamivudine

lamivudine 300 mg daily for 48 weeks

DRUG

Placebo monotherapy

Placebo to MK0518 twice daily

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00100048 - A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED) | Biotech Hunter | Biotech Hunter